Patrys Limited (ASX:PAB)

Market Cap	30.00M +629.0%
Revenue (ttm)	100.38K -93.1%
Net Income	-4.51M
EPS	-0.02
Shares Out	666.61M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,577,006
Open	0.0430
Previous Close	0.0420
Day's Range	0.0430 - 0.0460
52-Week Range	0.0120 - 0.0490
Beta	0.99
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 3, 2026

About Patrys

Patrys Limited, together with its subsidiaries, develops antibody technologies for the treatment of cancer and NETosis-driven inflammatory diseases. It develops PAT-DX1, a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10; and PAT-DX3 for treating primary and secondary brain cancers, and metastases that are associated with NETosis, or in combination with DNA damaging agents, such as radiation and other chemotherapy drugs. The company was incorporated in 2006 and is base...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 10
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: PAB

Financial Performance

In fiscal year 2025, Patrys's revenue was 828,540, a decrease of -40.57% compared to the previous year's 1.39 million. Losses were -3.01 million, -14.86% less than in 2024.